Please assess the completion status of the following clinical trial:

Trial Title: Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed ovarian epithelial, primary serous type peritoneal, or fallopian tube carcinoma~  * Patients with ovarian cancer of the clear cell histology are eligible. Histologic confirmation is preferably by biopsy or limited excision prior to neo-adjuvant treatment. If the diagnosis prior to neo-adjuvant chemotherapy is based on cytology, histologic confirmation is required prior to randomization. Histologic confirmation can be obtained at the time of debulking surgery by intra-operative frozen section, thus permitting intra-operative randomization, or by final pathologic review of the resected specimen if randomization is to be performed following debulking surgery.~ * Initial FIGO stage IIB-III disease~    * Stage IV disease allowed provided the only criterion for stage IV disease is the presence of a pleural effusion confirmed to be associated with positive cytology for ovarian cancer~* Completed ≥ 3 but no more than 4 courses of platinum-based neoadjuvant chemotherapy prior to the first debulking surgery~* Meets the following criteria for surgical treatment prior to randomization:~  * Initial Diagnosis: No debulking surgery was attempted or completed.~ * The patient's first cytoreductive (debulking) surgery must be after neoadjuvant chemotherapy (Delayed Primary Debulking). The delayed primary debulking surgery must be completed no more than 4 weeks after commencing administering of the last cycle of neoadjuvant chemotherapy and must be completed no more than 6 weeks prior to randomization.~ * Surgery will include total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy and any additional procedures required to achieve maximal cytoreduction with residual disease of 1 cm or less as assessed by the surgeon at the end of surgery.~    * Delayed primary debulking surgery must be completed no more than 4 weeks after the last course of neoadjuvant chemotherapy and must be completed no more than 6 weeks prior to randomization~ * Surgery will include total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and any additional procedures required to achieve maximal cytoreduction with residual disease of ≤ 1 cm as assessed by the surgeon at the end of surgery~* No borderline ovarian tumors (i.e., tumors of low malignant potential) alone~* No mucinous tumor~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Life expectancy ≥ 12 weeks~* Granulocyte count ≥ 1.5 x 10\^9/L~* Platelet count ≥ 100 x 10\^9/L~* Serum creatinine ≤ upper limit of normal (ULN) OR \> ULN to ≤ 1.25 ULN provided measured creatinine clearance is \> 60 mL/min~* Serum bilirubin normal~* AST/ALT ≤ 2.5 times ULN~* Fertile patients must use effective contraception~* Able (i.e., sufficiently fluent) and willing to complete the quality of life questionnaires~* Accessible for treatment and follow-up~* No history of other malignancy, except adequately treated nonmelanoma skin cancer, curatively treated carcinoma in situ of the cervix, or other solid tumors curatively treated with no evidence of disease for ≥ 5 years~* No uncontrolled atrial or ventricular arrhythmias including second or third degree heart block unless managed with implanted pacemaker~  * Patients with a history of first degree heart block are eligible~* No documented myocardial infarction within the past 6 months preceding randomization (pretreatment ECG evidence only of infarct will not exclude patients)~* No diagnosis of bowel obstruction~* No serious illness or medical condition which would not permit the patient to be managed according to protocol including, but not limited to, any of the following:~  * Prior allergic reactions to drugs containing cremophor or to compounds chemically related to cisplatin, paclitaxel, or carboplatin~ * Symptomatic congestive heart failure within the past 6 months or other conditions which would lead to a contraindication of a high-volume saline diuresis~ * History of significant neurologic or psychiatric disorder which would impair the ability to obtain consent~ * Active uncontrolled infection~ * Persistent peripheral neuropathy or hearing loss ≥ grade 2 resulting from prior therapy~ * Extensive intraperitoneal adhesion intra- or post-operatively which would impede intraperitoneal treatment delivery~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior therapy for ovarian cancer, except for neoadjuvant platinum-based chemotherapy and surgery~* No concurrent intraperitoneal adhesion barriers~* No other concurrent anticancer treatment, including cytotoxic agents, biological response modifiers, immunotherapy, anticancer hormone therapy, or investigational drug therapy~* No other concurrent experimental drugs or anticancer therapy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV carboplatin + IV paclitaxel (Type: ACTIVE_COMPARATOR): ARM 1: Paclitaxel 135 mg/m2 intravenous day 1 plus Carboplatin AUC 5 if measured GFR or AUC6 if estimated GFR intravenous day 1; Paclitaxel 60 mg/m2 intravenous day 8. Cycles given Q 21 days x 3 cycles
- IP cisplatin + IV/IP paclitaxel (Type: ACTIVE_COMPARATOR): ARM 2: Paclitaxel 135 mg/m2 intravenous day 1 plus Cisplatin 75 mg/m2 intraperitoneal day 1; Paclitaxel 60 mg/m2 intraperitoneal day 8. Cycles given Q 21 days x 3 cycles (Phase II cisplatin arm closed to accrual on 2014-FEB-03)
- IP carboplatin + IV/IP paclitaxel (Type: ACTIVE_COMPARATOR): ARM 3: Paclitaxel 135 mg/m2 intravenous day 1 plus Carboplatin AUC 5 if measured GFR or AUC6 if estimated GFR intraperitoneal day 1; Paclitaxel 60 mg/m2 intraperitoneal day 8. Cycles given Q 21 days x 3 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).